LeonaBio director granted 2,333 stock options

LeonaBio, Inc. director Fred Callori received a grant of stock options covering 2,333 shares of common stock at an exercise price of $8.35 per share.

Rhea-AI Filing Summary

LeonaBio, Inc. director Fred Callori received a grant of stock options covering 2,333 shares of common stock at an exercise price of $8.35 per share. These options vest on the earlier of June 23, 2027 or just before the next annual stockholder meeting after June 22, 2026 and expire on June 22, 2036.

Insider Trade Summary

Grant/Award: 2,333 shares

Grant/Award 1 txn

Insider Callori Fred

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,333	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,333 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.

Key Figures

Option grant size: 2,333 shares Exercise price: $8.35 per share Post-grant derivative holdings: 2,333 options +3 more

6 metrics

Option grant size 2,333 shares Stock options granted to director Fred Callori

Exercise price $8.35 per share Strike price of granted stock options

Post-grant derivative holdings 2,333 options Total options held following this grant

Option expiration date June 22, 2036 Expiration of director stock options

Latest vesting date June 23, 2027 Latest date when options will fully vest

Appointment date reference May 5, 2026 Board appointment date used for pro-rating grant

Key Terms

Stock Option (Right to Buy), Outside Director Compensation Policy, vest, annual meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Outside Director Compensation Policy financial

"option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy"

vest financial

"The shares subject to the option will vest on the earlier of (i) June 23, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of the Issuer's stockholders financial

"the day immediately before the date of the next annual meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LeonaBio (LONA) report for Fred Callori?

LeonaBio reported a stock option grant to director Fred Callori. He received options to acquire 2,333 shares of common stock as part of his outside director compensation, rather than buying shares on the open market, reflecting routine equity-based board compensation.

How many LeonaBio (LONA) shares are covered by Fred Callori’s new options?

The option grant covers 2,333 shares of LeonaBio common stock. These options give Callori the right to buy that number of shares in the future once they vest, aligning his interests with shareholders through potential equity ownership in the company.

What is the exercise price of Fred Callori’s LeonaBio (LONA) stock options?

The stock options have an exercise price of $8.35 per share. This means Callori can purchase LeonaBio common stock at $8.35 once the options vest, regardless of the market price at that time, subject to the grant’s terms and expiration date.

When do Fred Callori’s LeonaBio (LONA) stock options vest?

The options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting after June 22, 2026. This vesting schedule ties his equity compensation to continued board service over this period.

When do Fred Callori’s LeonaBio (LONA) stock options expire?

The granted options expire on June 22, 2036. After that expiration date, any unexercised portion of the 2,333 options can no longer be used to acquire shares, so potential value depends on LeonaBio’s share price and exercise before expiration.

Why did LeonaBio (LONA) grant stock options to Fred Callori?

The option grant was made under LeonaBio’s Outside Director Compensation Policy. It is pro-rated based on his appointment to the board on May 5, 2026, providing standard equity-based compensation intended to align director incentives with shareholder interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callori Fred

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.35	06/23/2026		A		2,333		(1)	06/22/2036	Common Stock	2,333	$0	2,333	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.

	/s/ Mark Worthington, Attorney in fact for Fred P. Callori	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)